<DOC>
	<DOCNO>NCT02297620</DOCNO>
	<brief_summary>The objective survey confirm safety Suglat Tablets use elderly .</brief_summary>
	<brief_title>The Survey Ipragliflozin Treatment Elderly type2 Diabetes Patients</brief_title>
	<detailed_description>Elderly patient ( 65 year old time first administration ) type 2 diabetes use Suglat Tablets within 3 month launch include study . Followings measure patient . 1 . Specify incidence rate adverse drug reaction associate decrease body fluid risk factor . 2 . Investigate occurrence urinary tract infection . 3 . Investigate occurrence adverse drug reaction patient high risk ( poorly control blood sugar level , concurrent organic abnormality urinary system , advance diabetic neuropathy , etc ) . 4 . Investigate occurrence adverse drug reaction . 5 . Factors may possibly influence safety Suglat Tablets .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>type 2 diabetes use Suglat Tablets within 3 month launch offlabel use patient</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>SGLT-2 inhibitor</keyword>
	<keyword>Elderly patient</keyword>
	<keyword>ASP1941</keyword>
</DOC>